|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NIN |
Gene summary for NIN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NIN | Gene ID | 51199 |
| Gene name | ninein | |
| Gene Alias | SCKL7 | |
| Cytomap | 14q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8N4C6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51199 | NIN | LZE2T | Human | Esophagus | ESCC | 7.18e-04 | 4.14e-01 | 0.082 |
| 51199 | NIN | LZE4T | Human | Esophagus | ESCC | 1.59e-03 | 1.20e-01 | 0.0811 |
| 51199 | NIN | LZE7T | Human | Esophagus | ESCC | 1.44e-03 | 3.47e-01 | 0.0667 |
| 51199 | NIN | LZE22T | Human | Esophagus | ESCC | 2.04e-05 | 4.38e-01 | 0.068 |
| 51199 | NIN | LZE24T | Human | Esophagus | ESCC | 1.93e-09 | 2.07e-01 | 0.0596 |
| 51199 | NIN | P2T-E | Human | Esophagus | ESCC | 3.68e-24 | 4.44e-01 | 0.1177 |
| 51199 | NIN | P4T-E | Human | Esophagus | ESCC | 3.45e-14 | 3.17e-01 | 0.1323 |
| 51199 | NIN | P5T-E | Human | Esophagus | ESCC | 1.54e-03 | 6.16e-02 | 0.1327 |
| 51199 | NIN | P8T-E | Human | Esophagus | ESCC | 7.78e-10 | 1.61e-01 | 0.0889 |
| 51199 | NIN | P9T-E | Human | Esophagus | ESCC | 1.63e-11 | 2.86e-01 | 0.1131 |
| 51199 | NIN | P10T-E | Human | Esophagus | ESCC | 1.03e-25 | 5.06e-01 | 0.116 |
| 51199 | NIN | P11T-E | Human | Esophagus | ESCC | 1.06e-05 | 2.84e-01 | 0.1426 |
| 51199 | NIN | P12T-E | Human | Esophagus | ESCC | 3.79e-18 | 4.20e-01 | 0.1122 |
| 51199 | NIN | P15T-E | Human | Esophagus | ESCC | 4.67e-29 | 6.14e-01 | 0.1149 |
| 51199 | NIN | P16T-E | Human | Esophagus | ESCC | 2.73e-25 | 5.32e-01 | 0.1153 |
| 51199 | NIN | P17T-E | Human | Esophagus | ESCC | 1.15e-08 | 2.92e-01 | 0.1278 |
| 51199 | NIN | P19T-E | Human | Esophagus | ESCC | 3.03e-05 | 3.53e-01 | 0.1662 |
| 51199 | NIN | P20T-E | Human | Esophagus | ESCC | 5.88e-12 | 3.06e-01 | 0.1124 |
| 51199 | NIN | P21T-E | Human | Esophagus | ESCC | 7.53e-13 | 2.98e-01 | 0.1617 |
| 51199 | NIN | P22T-E | Human | Esophagus | ESCC | 9.31e-17 | 2.98e-01 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0032886 | Liver | HCC | regulation of microtubule-based process | 123/7958 | 240/18723 | 3.69e-03 | 1.64e-02 | 123 |
| GO:004325420 | Oral cavity | OSCC | regulation of protein-containing complex assembly | 255/7305 | 428/18723 | 2.94e-18 | 3.15e-16 | 255 |
| GO:003133420 | Oral cavity | OSCC | positive regulation of protein-containing complex assembly | 153/7305 | 237/18723 | 1.18e-15 | 8.33e-14 | 153 |
| GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
| GO:190290520 | Oral cavity | OSCC | positive regulation of supramolecular fiber organization | 131/7305 | 209/18723 | 3.18e-12 | 1.27e-10 | 131 |
| GO:190290320 | Oral cavity | OSCC | regulation of supramolecular fiber organization | 211/7305 | 383/18723 | 9.45e-11 | 2.88e-09 | 211 |
| GO:005149518 | Oral cavity | OSCC | positive regulation of cytoskeleton organization | 135/7305 | 226/18723 | 1.98e-10 | 5.66e-09 | 135 |
| GO:005125820 | Oral cavity | OSCC | protein polymerization | 169/7305 | 297/18723 | 2.57e-10 | 7.17e-09 | 169 |
| GO:003227319 | Oral cavity | OSCC | positive regulation of protein polymerization | 88/7305 | 138/18723 | 3.24e-09 | 7.39e-08 | 88 |
| GO:003227120 | Oral cavity | OSCC | regulation of protein polymerization | 134/7305 | 233/18723 | 7.20e-09 | 1.51e-07 | 134 |
| GO:00310999 | Oral cavity | OSCC | regeneration | 114/7305 | 198/18723 | 8.54e-08 | 1.50e-06 | 114 |
| GO:00107209 | Oral cavity | OSCC | positive regulation of cell development | 159/7305 | 298/18723 | 3.06e-07 | 4.66e-06 | 159 |
| GO:00070204 | Oral cavity | OSCC | microtubule nucleation | 28/7305 | 35/18723 | 8.71e-07 | 1.19e-05 | 28 |
| GO:00467855 | Oral cavity | OSCC | microtubule polymerization | 53/7305 | 83/18723 | 3.96e-06 | 4.65e-05 | 53 |
| GO:00507696 | Oral cavity | OSCC | positive regulation of neurogenesis | 120/7305 | 225/18723 | 8.45e-06 | 9.02e-05 | 120 |
| GO:00705077 | Oral cavity | OSCC | regulation of microtubule cytoskeleton organization | 84/7305 | 148/18723 | 8.80e-06 | 9.33e-05 | 84 |
| GO:00022214 | Oral cavity | OSCC | pattern recognition receptor signaling pathway | 95/7305 | 172/18723 | 1.11e-05 | 1.15e-04 | 95 |
| GO:003134610 | Oral cavity | OSCC | positive regulation of cell projection organization | 176/7305 | 353/18723 | 1.94e-05 | 1.87e-04 | 176 |
| GO:00618427 | Oral cavity | OSCC | microtubule organizing center localization | 25/7305 | 33/18723 | 1.95e-05 | 1.87e-04 | 25 |
| GO:00516427 | Oral cavity | OSCC | centrosome localization | 24/7305 | 32/18723 | 3.83e-05 | 3.37e-04 | 24 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NIN | SNV | Missense_Mutation | novel | c.4249C>G | p.Gln1417Glu | p.Q1417E | Q8N4C6 | protein_coding | tolerated(0.58) | benign(0) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| NIN | SNV | Missense_Mutation | c.51N>G | p.Phe17Leu | p.F17L | Q8N4C6 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NIN | SNV | Missense_Mutation | novel | c.2894C>G | p.Ala965Gly | p.A965G | Q8N4C6 | protein_coding | tolerated(0.21) | benign(0.006) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NIN | SNV | Missense_Mutation | novel | c.517N>A | p.Gln173Lys | p.Q173K | Q8N4C6 | protein_coding | tolerated(0.14) | benign(0.006) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NIN | SNV | Missense_Mutation | c.3568N>G | p.Arg1190Gly | p.R1190G | Q8N4C6 | protein_coding | tolerated(0.09) | possibly_damaging(0.573) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NIN | SNV | Missense_Mutation | novel | c.4658N>T | p.Glu1553Val | p.E1553V | Q8N4C6 | protein_coding | deleterious(0) | benign(0.219) | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NIN | SNV | Missense_Mutation | novel | c.4739N>T | p.Ser1580Leu | p.S1580L | Q8N4C6 | protein_coding | tolerated(0.13) | benign(0.069) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NIN | SNV | Missense_Mutation | c.1444N>A | p.Arg482Ser | p.R482S | Q8N4C6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NIN | SNV | Missense_Mutation | rs774918630 | c.6116N>A | p.Arg2039Gln | p.R2039Q | Q8N4C6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| NIN | SNV | Missense_Mutation | c.5731N>C | p.Glu1911Gln | p.E1911Q | Q8N4C6 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |